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

Il network di riferimento per le aziende italiane

Biorek: la ricerca diventa impresa

AZIENDE 24 · APPROFONDIMENTO

Biorek

BIOTECHNOLOGY · RESEARCH · INNOVATION

La ricerca
diventa impresa.

Dalla ricerca scientifica alla biotecnologia applicata: Biorek sviluppa soluzioni innovative per la diagnostica molecolare del tumore renale e nuovi consumabili ad alte prestazioni per i laboratori.

2019
Anno di fondazione
2
Divisioni biotech
1.000
Partecipanti allo studio

SCIENTIFIC INNOVATION ✦MOLECULAR DIAGNOSTICS ✦LIQUID BIOPSY ✦LABORATORY CONSUMABLES ✦PRECISION & EFFICIENCY ✦
SCIENTIFIC INNOVATION ✦MOLECULAR DIAGNOSTICS ✦LIQUID BIOPSY ✦LABORATORY CONSUMABLES ✦PRECISION & EFFICIENCY ✦

01 · IDENTITÀ E VISIONE

Trasformare la conoscenza scientifica in innovazione concreta.

Fondata a Milano nel 2019, Biorek nasce dall’iniziativa della dott.ssa Alessandra Cinque, ricercatrice e biotecnologa, e del dott. Francesco Trevisani, medico specialista in Nefrologia e ricercatore.

Il progetto imprenditoriale prende forma a partire dall’attività di ricerca condotta presso l’IRCCS Ospedale San Raffaele di Milano, con l’obiettivo di portare i risultati della ricerca biomedica verso applicazioni concrete nei settori della diagnostica e delle tecnologie di laboratorio.

Oggi Biorek è una PMI innovativa che sviluppa due linee di business complementari, accomunate da una visione: valorizzare la ricerca attraverso soluzioni tecnologiche brevettate.

IL PERCORSO BIOREK
2019
Nasce Biorek
Dalla ricerca scientifica alla nuova iniziativa imprenditoriale.
2020–2025
Ricerca e sviluppo
Studio multicentrico, sviluppo di MiRECLE e crescita finanziaria.
2026
Nasce ALCINEX
Una nuova linea brevettata di consumabili per laboratorio.
2027
Espansione internazionale
Lancio commerciale globale pianificato per i nuovi prodotti.

02 · BIOREK IN NUMERI

La dimensione della ricerca

0
Partecipanti allo studio multicentrico
0
Campioni biologici nella biobanca
0
Capitale raccolto in tre aumenti
0
Finanziamento Smart&Start Italia

03 · RICERCA E DIAGNOSTICA

La sfida del tumore renale

DIVISIONE MiRECLE®
MICRO-RNA · LIQUID BIOPSY
MiRECLE®

MicroRNA REnal Cancer Liquid Evaluation: una piattaforma di test molecolari basata sull’analisi di biomarcatori circolanti nel sangue, sviluppata per supportare screening, diagnosi e prognosi del tumore renale.

TECNOLOGIA BREVETTATA
Pannelli di microRNA circolanti e algoritmi proprietari di machine learning.

Dalla ricerca ai biomarcatori

Il progetto nasce dalla necessità di sviluppare strumenti molecolari innovativi per una patologia in crescita, per la quale la biopsia liquida rappresenta un ambito di grande interesse scientifico.

Il lavoro di Biorek si concentra sui microRNA circolanti, molecole che possono contribuire a identificare specifiche firme molecolari associate alla malattia.

Attraverso analisi molecolari e algoritmi di machine learning, l’azienda ha individuato combinazioni di biomarcatori potenzialmente utili per differenti finalità di valutazione clinica.

SCREENING
MiRECLE-S
DIAGNOSI
MiRECLE-D
PROGNOSI
MiRECLE-P

LA SOLIDITÀ DELLA RICERCA

Un patrimonio scientifico costruito sul campo

Un progetto multicentrico internazionale ha consentito di raccogliere campioni biologici e informazioni cliniche per approfondire lo studio del tumore renale.

01

1.000 partecipanti

Pazienti con masse renali e soggetti di controllo coinvolti nello studio multicentrico internazionale.

02

22.000 campioni

Sangue, plasma e urine hanno contribuito alla costituzione di una biobanca di grande valore scientifico.

03

Follow-up triennale

La raccolta dei dati clinici prima e dopo l’intervento ha previsto il monitoraggio dei pazienti per tre anni.

04

Machine learning

L’analisi molecolare ha permesso di individuare firme di biomarcatori attraverso algoritmi dedicati.

STATO DELLO SVILUPPO
MiRECLE è in fase di validazione scientifica
Il test è protetto da brevetto internazionale, la cui titolarità esclusiva è detenuta da Biorek S.r.l.

04 · LA NUOVA FRONTIERA

Innovare il lavoro in laboratorio

DIVISIONE ALCINEX®
ALCINEX

Precisione, efficienza e produttività

Nel 2026 Biorek amplia il proprio portafoglio brevettuale con ALCINEX, una nuova linea di consumabili innovativi destinati alla ricerca di base e alla diagnostica.

La linea nasce dall’esperienza diretta maturata nei laboratori e dall’intuizione della dott.ssa Cinque: sviluppare reservoir progettati per migliorare le prestazioni dei sistemi di pipettaggio manuale e automatizzato.

L’obiettivo è ottimizzare i processi, ridurre gli sprechi di reagenti e campioni biologici, limitare il rischio di errore umano e rendere più efficienti le operazioni quotidiane.

BREVETTATI
ALTA PRECISIONE
LIQUID HANDLING
Reservoir ALCINEX a due compartimenti

ALCINEX RESERVOIRS

Una nuova generazione di consumabili

Progettati per garantire affidabilità anche con volumi ridotti e migliorare il recupero di reagenti e campioni.

LA GAMMA ALCINEX

Tre configurazioni. Nuove possibilità operative.

I reservoir sono progettati per differenti configurazioni di pipettaggio multicanale, adattandosi alle esigenze dei flussi di lavoro di laboratorio.

Reservoir 2 compartimenti

CONFIGURAZIONE 01

2 compartimenti

Capacità massima di 10 ml nel compartimento principale e 5 ml in quello secondario.

PIPETTAGGIO 8 / 16 / 12 / 24 CANALI
Reservoir 12 compartimenti

CONFIGURAZIONE 02

12 compartimenti

Capacità massima di 1,2 ml per compartimento. Consente di gestire simultaneamente campioni o reagenti differenti.

PIPETTAGGIO 8 / 12 CANALI
Reservoir 24 compartimenti

CONFIGURAZIONE 03

24 compartimenti

Capacità massima di 600 µl per compartimento, per gestire contemporaneamente differenti liquidi.

PIPETTAGGIO 16 / 24 CANALI

IL VALORE TECNOLOGICO

Meno sprechi. Maggiore precisione.

Le caratteristiche tecniche dei reservoir ALCINEX sono progettate per ottimizzare l’utilizzo dei volumi di reagenti e campioni.

45 µl
Volume minimo di caricamento
Comparto principale del reservoir a 2 compartimenti (45 ± 2 µl).
5 µl
Formato a 12 compartimenti
Volume minimo di caricamento per compartimento (5 ± 1 µl).
3 µl
Formato a 24 compartimenti
Volume minimo di caricamento per compartimento (3 ± 0,5 µl).

Caratteristiche comuni

PCR-clean
RNase-free
DNase-free
Pyrogen-free
PCR inhibitor-free
Endotoxin-free

Disponibili in polistirene o polipropilene, in versione sterile e non sterile.

05 · LE PERSONE E LA RICERCA

Le competenze alla base del progetto

L’esperienza scientifica e clinica dei fondatori è il punto di partenza del percorso di innovazione Biorek.

Alessandra Cinque

PRESIDENTE · CO-FOUNDER

Alessandra Cinque

Biotecnologa e ricercatrice, ha maturato la propria esperienza nella ricerca traslazionale presso l’IRCCS Ospedale San Raffaele, contribuendo allo sviluppo delle firme molecolari brevettate alla base di MiRECLE.

Francesco Trevisani

CEO · CO-FOUNDER

Francesco Trevisani

Medico specialista in Nefrologia e ricercatore, ha contribuito alla nascita del progetto a partire dall’attività scientifica svolta al San Raffaele, unendo competenze cliniche e ricerca biomedica.

06 · SVILUPPO E INVESTIMENTI

Una crescita sostenuta da capitali e competenze

In sette anni di attività Biorek ha consolidato il proprio percorso imprenditoriale, passando da startup innovativa a PMI innovativa e attirando risorse finanziarie a sostegno della ricerca e dello sviluppo.

Il percorso è stato sostenuto da una compagine societaria internazionale e diversificata, composta da investitori privati, società e istituzioni scientifiche.

RISORSE RACCOLTE
1,81 M€
Attraverso tre aumenti di capitale: 2019, 2023 e 2025.
+600.000 €
Ottenuti attraverso il programma Smart&Start Italia di Invitalia.
250.000 €
Raccolti con la campagna di crowdlending sulla piattaforma Crowdlender di Opstart nel gennaio 2025, in soli cinque giorni.

07 · PROSPETTIVE

Due divisioni, una strategia di crescita

Biorek punta a strutturare il proprio modello di business su due divisioni biotech sinergiche, con prospettive di sviluppo sui mercati internazionali.

DIVISIONE 01

MiRECLE®

Diagnostica molecolare avanzata del tumore renale attraverso test basati su biopsia liquida e biomarcatori.

DIVISIONE 02

ALCINEX®

Consumabili innovativi e soluzioni per il pipettaggio e la gestione dei liquidi nei laboratori di ricerca e diagnostica.

PROSSIMA TAPPA

2027 · Lancio commerciale globale ALCINEX

Dopo la presentazione in anteprima internazionale dei prototipi a MEDICA Düsseldorf, Biorek pianifica il lancio commerciale su scala globale della nuova linea di consumabili.

4° ROUND DI INVESTIMENTO · FINE 2026 / Q1 2027

Biorek

BIOREK · SCIENTIFIC INNOVATION

Dalla ricerca al futuro della biotecnologia.

Con MiRECLE e ALCINEX, Biorek sviluppa due percorsi di innovazione che mettono la ricerca scientifica al centro di nuove opportunità per la diagnostica e i laboratori.

VISITA IL SITO BIOREK ↗

AZIENDE 24 · APPROFONDIMENTO
Biorek S.r.l. · Milano · www.biorek.eu
Informazioni aziendali e scientifiche elaborate sulla base dei materiali forniti e delle informazioni pubblicate sul sito Biorek.